Article
Role of ERCC1 variants in response to chemotherapy and clinical outcome of advanced non-small cell lung cancer.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine - 1 May 2014
Huang Shao-jun, Wang Yu-fei, Jin Zhi-yong, Sun Jia-yang, Guo Zhan-lin
Abstract excerpt
Excision repair cross-complementation group 1 (ERCC1) and xeroderma pigmentosum-F (XPF) in the nucleotide excision repair pathway have been effectively repairing DNA damage induced by chemotherapeutic agents. We conducted a cohort study to assess the associations of ERCC1 and XPF polymorphisms with response to platinum-based chemotherapy and clinical outcome of non-small-cell lung cancer (NSCLC). One hundred...
Topics
Join the communities discussing this publication.
